WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) — Disc Drugs, Inc. (NASDAQ:), a clinical-stage biopharmaceutical firm targeted on the invention, growth, and commercialization of novel remedies for sufferers affected by severe hematologic illnesses, will host a convention name to debate suggestions acquired from its Kind C assembly on bitopertin in EPP with the U.S. Meals and Drug Administration (FDA). The convention name will likely be held on Tuesday, January 21, at 8:00 am EST.
Convention Name Info
Please register for the occasion on the Occasions and Displays web page of Disc’s web site at https://ir.discmedicine.com/.
About Bitopertin
Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that’s designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on growing crimson blood cells and is required to provide adequate glycine for heme biosynthesis and assist erythropoiesis. Disc is planning to develop bitopertin as a possible remedy for a variety of hematologic illnesses together with erythropoietic porphyrias, the place it has potential to be the primary disease-modifying remedy. Bitopertin has been studied in a number of scientific trials in sufferers with EPP, together with the Part 2 open-label BEACON trial, the Part 2 double-blind, placebo-controlled AURORA trial, and an open-label extension HELIOS trial.
Bitopertin is an investigational agent and isn’t accredited to be used as a remedy in any jurisdiction worldwide. Disc obtained international rights to bitopertin below a license settlement from Roche in Could 2021.
About Erythropoietic Protoporphyria (EPP)
Erythropoietic protoporphyria (EPP), together with X-linked Protoporphyria (XLP), is a uncommon, debilitating and probably life-threatening illness brought on by mutations that have an effect on heme biosynthesis, ensuing within the accumulation of a poisonous, photoactive intermediate referred to as protoporphyrin IX (PPIX). This causes extreme reactions when sufferers are uncovered to daylight, characterised by excruciating ache, edema, burning sensations and potential blistering and disfigurement. PPIX additionally accumulates within the hepatobiliary system and may end up in problems together with gallstones, cholestasis, and liver harm in 20-30% of sufferers and in excessive circumstances liver failure. Present customary of care includes excessive measures to keep away from daylight, together with limiting outside actions to nighttime, use of protecting clothes and opaque shields, and ache administration. This has a big impression on the psychosocial growth, high quality of life, and each day actions of sufferers, notably in younger kids and households. There’s at present no treatment for EPP and just one FDA-approved remedy, a surgically implanted artificial hormone designed to stimulate melanin manufacturing referred to as Scenesse ® (afamelanotide).
About Disc Drugs
Disc Drugs is a clinical-stage biopharmaceutical firm dedicated to discovering, growing, and commercializing novel remedies for sufferers that suffer from severe hematologic illnesses. We’re constructing a portfolio of revolutionary, probably first-in-class therapeutic candidates that purpose to handle a large spectrum of hematologic illnesses by focusing on elementary organic pathways of crimson blood cell biology, particularly heme biosynthesis and iron homeostasis. For extra data, please go to www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
